Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.43 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | MDM4 | O15151 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8933069 | 0.87 | FABP5 (0.42) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL377644 | 0.87 | KMT2A (0.42) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL11902048 | 0.85 | KMT2A (0.45) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL3173765 | 0.82 | KMT2A (0.44) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL6796558 | 0.81 | KMT2A (0.43) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL341372 | 0.81 | KMT2A (0.43) | KMT2AFABP5FABP7EPHX2OPRD1 | |
| SCHEMBL1869833 | 0.80 | FABP5 (0.50) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL6651104 | 0.80 | KMT2A (0.41) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL2943202 | 0.79 | KMT2A (0.41) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL2355443 | 0.79 | KMT2A (0.49) | KMT2AFABP5FABP7EPHX2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101257-A1 | PROCESSES FOR PREPARING AMINO-SUBSTITUTED GAMMA-LACTAMS | UNIVERSITE DE MONTREAL (CA) | 2012-04-26 | — | — | US | disclosed |
| EP-2408759-A1 | PROCESSES FOR PREPARING AMINO-SUBSTITUTED GAMMA-LACTAMS | Valorisation-Recherche, Société en Commandite (CA) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010105367-A1 | PROCESSES FOR PREPARING AMINO-SUBSTITUTED GAMMA-LACTAMS | VALORISATION-RECHERCHE SOCIETE EN COMMANDITE (CA) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010106441-A2 | PEPTIDOMIMETICS FOR MODULATING INTERLEUKIN-1 RECEPTOR | CENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINE (CA) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101257-A1 | PROCESSES FOR PREPARING AMINO-SUBSTITUTED GAMMA-LACTAMS | QPCT, GLUL, ASNS | KMT2A 4277/4885FABP5 3472/4885FABP7 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.